Mediven's MDx Tests Get CE-IVD Mark | GenomeWeb

NEW YORK (GenomeWeb) – Malaysian diagnostics firm Medical Innovation Ventures (Mediven) said that it received the CE-IVD mark for its molecular diagnostic tests for influenza and cholera. 

Its GenoAmp Real-Time RT-PCR kit for influenza A and B detects influenza A serotypes H1N1 and H3N2, and influenza B from viral RNA in a single tube within four hours, the company said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.